Spine BioPharma Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $385K

  • Investors
  • 4

Spine BioPharma General Information

Description

Developer of non-surgical therapies designed to reduce pain, restore function, and slow or stop pathological spinal disease progression. The company offers a research-focused biopharmaceutical platform with clinically oriented therapies that aim to reduce pain, restore mobility, modulate pathological processes, and broaden potential treatment indications, enabling patients suffering from degenerative disc disease and related spinal conditions to access new medical options that may improve quality of life and slow disease progression.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 505 Park Avenue
  • 14th Floor
  • New York, NY 10022
  • United States
+1 (212)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 505 Park Avenue
  • 14th Floor
  • New York, NY 10022
  • United States
+1 (212)

Spine BioPharma Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Spine BioPharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 05-Jun-2026 $385K Completed Clinical Trials - Phase 3
5. Later Stage VC (Series D) 18-Dec-2024 Completed Clinical Trials - Phase 3
4. Later Stage VC (Series C) 11-Oct-2023 Completed Clinical Trials - Phase 3
3. Later Stage VC (Series B) 23-Mar-2022 Completed Clinical Trials - Phase 1
2. Later Stage VC (Series A) 15-Apr-2021 $10M $11.3M Completed Product Development
1. Seed Round $1.32M $1.32M Completed Product Development
To view Spine BioPharma’s complete valuation and funding history, request access »

Spine BioPharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D
Series C
Series B
Series A 1,980,245 $0.010000 $3.03 $3.03 1x $3.03 6.1%
Seed 3,300,000 $0.010000 $0.4 $0.4 1x $0.4 10.16%
To view Spine BioPharma’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Spine BioPharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of non-surgical therapies designed to reduce pain, restore function, and slow or stop pathological spinal dise
Drug Discovery
New York, NY
12 As of 2026

Melville, NY
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Spine BioPharma Competitors (3)

One of Spine BioPharma’s 3 competitors is BioRestorative Therapies, a Corporation company based in Melville, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BioRestorative Therapies Corporation Melville, NY
Brainstorm Cell Therapeutics Corporation New York, NY
Biosplice Therapeutics Private Equity-Backed San Diego, CA
You’re viewing 3 of 3 competitors. Get the full list »

Spine BioPharma Patents

Spine BioPharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024172859-A1 Peptide formulations Inactive 17-Feb-2023
WO-2024172860-A1 Peptides and formulations thereof for treatment of degenerative disc disease Inactive 17-Feb-2023

Spine BioPharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Spine BioPharma Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Blindspot Ventures Venture Capital Minority
Cercano Management PE/Buyout Minority
Pacira BioSciences Corporation Minority
Viscogliosi Bros. PE/Buyout Minority
To view Spine BioPharma’s complete investors history, request access »

Spine BioPharma FAQs

  • When was Spine BioPharma founded?

    Spine BioPharma was founded in 2015.

  • Where is Spine BioPharma headquartered?

    Spine BioPharma is headquartered in New York, NY.

  • What is the size of Spine BioPharma?

    Spine BioPharma has 12 total employees.

  • What industry is Spine BioPharma in?

    Spine BioPharma’s primary industry is Drug Discovery.

  • Is Spine BioPharma a private or public company?

    Spine BioPharma is a Private company.

  • What is Spine BioPharma’s current revenue?

    The current revenue for Spine BioPharma is .

  • How much funding has Spine BioPharma raised over time?

    Spine BioPharma has raised $55.5M.

  • Who are Spine BioPharma’s investors?

    Blindspot Ventures, Cercano Management, Pacira BioSciences, and Viscogliosi Bros. have invested in Spine BioPharma.

  • Who are Spine BioPharma’s competitors?

    BioRestorative Therapies, Brainstorm Cell Therapeutics, and Biosplice Therapeutics are competitors of Spine BioPharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process